
zzso is a zzso alternative to zzso zzso has been administered as an intravenous infusion to 17 patients in a Phase I clinical zzso The zzso zzso were zzso and vomiting which were observed in all patients at 500 zzso zzso and zzso The dose was not escalated above zzso zzso zzso where zzso and vomiting were zzso prolonged zzso than 24 zzso and poorly controlled by zzso zzso zzso and zzso zzso were not zzso Neurological toxicity was not observed at low doses (less than 500 zzso but could not be determined at higher doses due to intensive zzso zzso zzso studies zzso zzso zzso indicated that zzso plasma levels are zzso and that the zzso zzso zzso is prolonged in patients with abnormal liver zzso It is concluded that the severe toxicity of zzso will limit the clinical utility of this compound and hence Phase II trials are not zzso 

